Anxiety and depression stories

Oct 30, 2026

EMA reviews Lundbeck's Deanxit after reports of serious neurological side effects

The European Medicines Agency has begun a safety review of Deanxit, a depression and anxiety medication made by Danish drugmaker H Lundbeck, following reports of serious neurological and psychiatric side effects.

Oct 30, 20262 sources

Top claims

▪Danish drugmaker H Lundbeck declined to comment on the European Medicines Agency's safety review of Deanxit.
▪Belgium's medicines agency raised concerns about the long-term use of Deanxit, noting that flupentixol has been linked to potentially irreversible serious side effects.
▪The European Medicines Agency's Pharmacovigilance Risk Assessment Committee will evaluate Deanxit data to decide whether to retain, amend, suspend, or revoke the drug's marketing authorization, with the review expected to conclude by March.

Subtopics

Adverse event reporting (FAERS)1 Anti-depressant1 Drug Policy, Pricing & Approval1 Drug safety & pharmacovigilance1 Mental Health & Wellbeing1 Neurological disorders1 Pharmaceutical Industry1

Related timelines